Pretty much what Visolis and LCY-Bio has been pointing to they can use the BioAmber assets, technology, personnel and IP's along with their own to develop better cost effective alternatives.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.